Clementia Pharmaceuticals (CMTA) Releases Earnings Results, Beats Estimates By $0.09 EPS

Clementia Pharmaceuticals (NASDAQ:CMTA) posted its earnings results on Thursday. The company reported ($0.34) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.09, MarketWatch Earnings reports.

Clementia Pharmaceuticals stock traded up $0.11 during midday trading on Friday, hitting $9.00. 61,401 shares of the company’s stock were exchanged, compared to its average volume of 93,854. Clementia Pharmaceuticals has a 12-month low of $8.10 and a 12-month high of $20.15. The company has a market capitalization of $271.82 million and a P/E ratio of -1.13.

CMTA has been the topic of a number of recent analyst reports. ValuEngine raised shares of Clementia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Zacks Investment Research downgraded shares of Clementia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, May 14th. Finally, Wedbush reissued an “outperform” rating and set a $26.00 price objective on shares of Clementia Pharmaceuticals in a research report on Friday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $26.60.

About Clementia Pharmaceuticals

Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial.

Featured Article: Momentum Indicator: Relative Strength Index

Earnings History for Clementia Pharmaceuticals (NASDAQ:CMTA)

Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply